The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …

At 2.8 million infections due to AR pathogens and 35,900 attributable deaths each year (2),
AR is still a very real problem in the United States. Given that sicker patients not only tend to …

Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …

Abstract Background Antibiotic resistance in Gram-negative resistance has developed
without a commensurate response in the successful development of antibiotic agents …

Microbial resistance is a serious threat to human health worldwide. Among the World Health
Organisation's list of priority resistant bacteria, three are listed as critical—the highest level of …

Background We conducted this study to describe the clinical characteristics, microbiology,
and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug …

This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for
different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 …